IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Immune-mediated Liver Injury in Hepatitis B Virus Infection

  • Oh, In Soo (Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST) ;
  • Park, Su-Hyung (Laboratory of Translational Immunology and Vaccinology, Graduate School of Medical Science and Engineering, KAIST)
  • Received : 2015.06.20
  • Accepted : 2015.08.02
  • Published : 2015.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Hepatitis B virus (HBV) is responsible for approximately 350 million chronic infections worldwide and is a leading cause of broad-spectrum liver diseases such as hepatitis, cirrhosis and liver cancer. Although it has been well established that adaptive immunity plays a critical role in viral clearance, the pathogenetic mechanisms that cause liver damage during acute and chronic HBV infection remain largely known. This review describes our current knowledge of the immune-mediated pathogenesis of HBV infection and the role of immune cells in the liver injury during hepatitis B.

Keywords

References

  1. Park, S. H., and B. Rehermann. 2014. Immune responses to HCV and other hepatitis viruses. Immunity 40: 13-24. https://doi.org/10.1016/j.immuni.2013.12.010
  2. Chisari, F. V., M. Isogawa, and S. F. Wieland. 2010. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 58: 258-266. https://doi.org/10.1016/j.patbio.2009.11.001
  3. Ocama, P., C. K. Opio, and W. M. Lee. 2005. Hepatitis B virus infection: current status. Am. J. Med. 118: 1413.
  4. Guidotti, L. G., and F. V. Chisari. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1: 23-61. https://doi.org/10.1146/annurev.pathol.1.110304.100230
  5. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825-829. https://doi.org/10.1126/science.284.5415.825
  6. Thimme, R., S. Wieland, C. Steiger, J. Ghrayeb, K. A. Reimann, R. H. Purcell, and F. V. Chisari. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77: 68-76. https://doi.org/10.1128/JVI.77.1.68-76.2003
  7. Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229. https://doi.org/10.1038/nri1573
  8. Maini, M. K., C. Boni, C. K. Lee, J. R. Larrubia, S. Reignat, G. S. Ogg, A. S. King, J. Herberg, R. Gilson, A. Alisa, R. Williams, D. Vergani, N. V. Naoumov, C. Ferrari, and A. Bertoletti. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191: 1269-1280. https://doi.org/10.1084/jem.191.8.1269
  9. Sells, M. A., M. L. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U. S. A. 84: 1005-1009. https://doi.org/10.1073/pnas.84.4.1005
  10. Quasdorff, M., M. Hosel, M. Odenthal, U. Zedler, F. Bohne, P. Gripon, H. P. Dienes, U. Drebber, D. Stippel, T. Goeser, and U. Protzer. 2008. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell. Microbiol. 10: 1478-1490. https://doi.org/10.1111/j.1462-5822.2008.01141.x
  11. Schulze-Bergkamen, H., A. Untergasser, A. Dax, H. Vogel, P. Buchler, E. Klar, T. Lehnert, H. Friess, M. W. Buchler, M. Kirschfink, W. Stremmel, P. H. Krammer, M. Muller, and U. Protzer. 2003. Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection. J. Hepatol. 38: 736-744.
  12. Guidotti, L. G., B. Matzke, H. Schaller, and F. V. Chisari. 1995. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69: 6158-6169.
  13. McMahon, B. J. 2009. The natural history of chronic hepatitis B virus infection. Hepatology 49: S45-S55. https://doi.org/10.1002/hep.22898
  14. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13: 29-60. https://doi.org/10.1146/annurev.iy.13.040195.000333
  15. Ferrari, C., G. Missale, C. Boni, and S. Urbani. 2003. Immunopathogenesis of hepatitis B. J. Hepatol. 39 Suppl 1: S36-S42. https://doi.org/10.1016/S0168-8278(03)00137-5
  16. Ganem, D., and A. M. Prince. 2004. Hepatitis B virus infection--natural history and clinical consequences. N. Engl. J. Med. 350: 1118-1129. https://doi.org/10.1056/NEJMra031087
  17. Servet-Delprat, C., P. O. Vidalain, O. Azocar, D. F. Le, A. Fischer, and C. Rabourdin-Combe. 2000. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J. Virol. 74: 4387-4393. https://doi.org/10.1128/JVI.74.9.4387-4393.2000
  18. Su, F., C. N. Theodosis, and R. J. Schneider. 2001. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J. Virol. 75: 215-225. https://doi.org/10.1128/JVI.75.1.215-225.2001
  19. Terradillos, O., T. Pollicino, H. Lecoeur, M. Tripodi, M. L. Gougeon, P. Tiollais, and M. A. Buendia. 1998. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 17: 2115-2123. https://doi.org/10.1038/sj.onc.1202432
  20. Kim, K. H., and B. L. Seong. 2003. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J. 22: 2104-2116. https://doi.org/10.1093/emboj/cdg210
  21. Miao, J., G. G. Chen, S. Y. Chun, and P. P. Lai. 2006. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett. 236: 115-124. https://doi.org/10.1016/j.canlet.2005.05.014
  22. Shirakata, Y., and K. Koike. 2003. Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. J. Biol. Chem. 278: 22071-22078. https://doi.org/10.1074/jbc.M301606200
  23. Brenner, C., L. Galluzzi, O. Kepp, and G. Kroemer. 2013. Decoding cell death signals in liver inflammation. J. Hepatol. 59: 583-594. https://doi.org/10.1016/j.jhep.2013.03.033
  24. Kroemer, G., L. Galluzzi, and C. Brenner. 2007. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87: 99-163. https://doi.org/10.1152/physrev.00013.2006
  25. Kirby, J., K. A. Levin, and J. Inchley. 2013. Socio-environmental influences on physical activity among young people: a qualitative study. Health Educ. Res. 28: 954-969. https://doi.org/10.1093/her/cyt085
  26. Krtolica, A., S. Parrinello, S. Lockett, P. Y. Desprez, and J. Campisi. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U. S. A. 98: 12072-12077. https://doi.org/10.1073/pnas.211053698
  27. Acs, G., M. A. Sells, R. H. Purcell, P. Price, R. Engle, M. Shapiro, and H. Popper. 1987. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc. Natl. Acad. Sci. U. S. A. 84: 4641-4644. https://doi.org/10.1073/pnas.84.13.4641
  28. Diao, J., A. A. Khine, F. Sarangi, E. Hsu, C. Iorio, L. A. Tibbles, J. R. Woodgett, J. Penninger, and C. D. Richardson. 2001. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J. Biol. Chem. 276: 8328-8340. https://doi.org/10.1074/jbc.M006026200
  29. Pan, J., L. X. Duan, B. S. Sun, and M. A. Feitelson. 2001. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J. Gen. Virol. 82: 171-182. https://doi.org/10.1099/0022-1317-82-1-171
  30. Shih, W. L., M. L. Kuo, S. E. Chuang, A. L. Cheng, and S. L. Doong. 2000. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 275: 25858-25864. https://doi.org/10.1074/jbc.M003578200
  31. Marusawa, H., S. Matsuzawa, K. Welsh, H. Zou, R. Armstrong, I. Tamm, and J. C. Reed. 2003. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22: 2729-2740. https://doi.org/10.1093/emboj/cdg263
  32. Lee, Y. I., S. Kang-Park, S. I. Do, and Y. I. Lee. 2001. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 276: 16969-16977. https://doi.org/10.1074/jbc.M011263200
  33. Elmore, L. W., A. R. Hancock, S. F. Chang, X. W. Wang, S. Chang, C. P. Callahan, D. A. Geller, H. Will, and C. C. Harris. 1997. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 94: 14707-14712. https://doi.org/10.1073/pnas.94.26.14707
  34. Huo, T. I., X. W. Wang, M. Forgues, C. G. Wu, E. A. Spillare, C. Giannini, C. Brechot, and C. C. Harris. 2001. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20: 3620-3628. https://doi.org/10.1038/sj.onc.1204495
  35. Arzberger, S., M. Hosel, and U. Protzer. 2010. Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus. J. Virol. 84: 11994-12001. https://doi.org/10.1128/JVI.00653-10
  36. Assrir, N., P. Soussan, D. Kremsdorf, and J. M. Rossignol. 2010. Role of the hepatitis B virus proteins in pro- and anti-apoptotic processes. Front. Biosci. (Landmark Ed.) 15: 12-24. https://doi.org/10.2741/3602
  37. Su, F., and R. J. Schneider. 1997. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 94: 8744-8749. https://doi.org/10.1073/pnas.94.16.8744
  38. Lindros, K. O., T. Oinonen, J. Issakainen, P. Nagy, and S. S. Thorgeirsson. 1997. Zonal distribution of transcripts of four hepatic transcription factors in the mature rat liver. Cell Biol. Toxicol. 13: 257-262. https://doi.org/10.1023/A:1007479223229
  39. Locaputo, S., T. L. Carrick, and J. A. Bezerra. 1999. Zonal regulation of gene expression during liver regeneration of urokinase transgenic mice. Hepatology 29: 1106-1113. https://doi.org/10.1002/hep.510290434
  40. Sitia, G., R. Aiolfi, L. P. Di, M. Mainetti, A. Fiocchi, F. Mingozzi, A. Esposito, Z. M. Ruggeri, F. V. Chisari, M. Iannacone, and L. G. Guidotti. 2012. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl. Acad. Sci. U. S. A. 109: E2165-E2172. https://doi.org/10.1073/pnas.1209182109
  41. Iannacone, M., G. Sitia, M. Isogawa, P. Marchese, M. G. Castro, P. R. Lowenstein, F. V. Chisari, Z. M. Ruggeri, and L. G. Guidotti. 2005. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 11: 1167-1169. https://doi.org/10.1038/nm1317
  42. Norris, S., C. Collins, D. G. Doherty, F. Smith, G. McEntee, O. Traynor, N. Nolan, J. Hegarty, and C. O'Farrelly. 1998. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J. Hepatol. 28: 84-90.
  43. Ramadori, G., and B. Saile. 2004. Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology 127: 997-1000. https://doi.org/10.1053/j.gastro.2004.07.041
  44. Bonorino, P., M. Ramzan, X. Camous, T. Dufeu-Duchesne, M. A. Thelu, N. Sturm, A. Dariz, C. Guillermet, M. Pernollet, J. P. Zarski, P. N. Marche, V. Leroy, and E. Jouvin-Marche. 2009. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 51: 458-467. https://doi.org/10.1016/j.jhep.2009.05.030
  45. Oliviero, B., S. Varchetta, E. Paudice, G. Michelone, M. Zaramella, D. Mavilio, F. F. De, S. Bruno, and M. U. Mondelli. 2009. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137: 1151-1160. https://doi.org/10.1053/j.gastro.2009.05.047
  46. Zhao, J., Y. Li, L. Jin, S. Zhang, R. Fan, Y. Sun, C. Zhou, Q. Shang, W. Li, Z. Zhang, and F. S. Wang. 2012. Natural killer cells are characterized by the concomitantly increased interferongamma and cytotoxicity in acute resolved hepatitis B patients. PLoS One 7: e49135. https://doi.org/10.1371/journal.pone.0049135
  47. Varchetta, S., D. Mele, S. Mantovani, B. Oliviero, E. Cremonesi, S. Ludovisi, G. Michelone, M. Alessiani, R. Rosati, M. Montorsi, and M. U. Mondelli. 2012. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 56: 841-849. https://doi.org/10.1002/hep.25723
  48. Nattermann, J., G. Feldmann, G. Ahlenstiel, B. Langhans, T. Sauerbruch, and U. Spengler. 2006. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55: 869-877. https://doi.org/10.1136/gut.2005.076463
  49. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220. https://doi.org/10.1146/annurev.immunol.17.1.189
  50. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25-36. https://doi.org/10.1016/S1074-7613(00)80295-2
  51. Dunn, C., M. Brunetto, G. Reynolds, T. Christophides, P. T. Kennedy, P. Lampertico, A. Das, A. R. Lopes, P. Borrow, K. Williams, E. Humphreys, S. Afford, D. H. Adams, A. Bertoletti, and M. K. Maini. 2007. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204: 667-680. https://doi.org/10.1084/jem.20061287
  52. Zhang, Z., S. Zhang, Z. Zou, J. Shi, J. Zhao, R. Fan, E. Qin, B. Li, Z. Li, X. Xu, J. Fu, J. Zhang, B. Gao, Z. Tian, and F. S. Wang. 2011. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53: 73-85. https://doi.org/10.1002/hep.23977
  53. Arababadi, M. K., A. A. Pourfathollah, A. Jafarzadeh, and G. Hassanshahi. 2010. Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients. Hepat. Mon. 10: 31-35.
  54. Arababadi, M. K., A. A. Pourfathollah, A. Jafarzadeh, G. Hassanshahi, S. Daneshmandi, A. Shamsizadeh, and D. Kennedy. 2011. Non-association of IL-12 +1188 and IFN-gamma +874 polymorphisms with cytokines serum level in occult HBV infected patients. Saudi. J. Gastroenterol. 17: 30-35. https://doi.org/10.4103/1319-3767.74461
  55. Khorramdelazad, H., G. Hassanshahi, A. B. Nasiri, and A. M. Kazemi. 2012. High Serum Levels of TGF-beta in Iranians With Chronic HBV Infection. Hepat. Mon. 12: e7581.
  56. Wieland, S. F., and F. V. Chisari. 2005. Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79: 9369-9380. https://doi.org/10.1128/JVI.79.15.9369-9380.2005
  57. Bigger, C. B., K. M. Brasky, and R. E. Lanford. 2001. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75: 7059-7066. https://doi.org/10.1128/JVI.75.15.7059-7066.2001
  58. Su, A. I., J. P. Pezacki, L. Wodicka, A. D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R. H. Purcell, P. G. Schultz, and F. V. Chisari. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 99: 15669-15674. https://doi.org/10.1073/pnas.202608199
  59. Seeger, C., and W. S. Mason. 2000. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64: 51-68. https://doi.org/10.1128/MMBR.64.1.51-68.2000
  60. Bertoletti, A., C. Ferrari, F. Fiaccadori, A. Penna, R. Margolskee, H. J. Schlicht, P. Fowler, S. Guilhot, and F. V. Chisari. 1991. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. U. S. A. 88: 10445-10449. https://doi.org/10.1073/pnas.88.23.10445
  61. Missale, G., A. Redeker, J. Person, P. Fowler, S. Guilhot, H. J. Schlicht, C. Ferrari, and F. V. Chisari. 1993. HLA-A31- and HLAAw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J. Exp. Med. 177: 751-762. https://doi.org/10.1084/jem.177.3.751
  62. Rehermann, B., P. Fowler, J. Sidney, J. Person, A. Redeker, M. Brown, B. Moss, A. Sette, and F. V. Chisari. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181: 1047-1058. https://doi.org/10.1084/jem.181.3.1047
  63. Baumert, T. F., R. Thimme, and W. F. von. 2007. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 13: 82-90. https://doi.org/10.3748/wjg.v13.i1.82
  64. Wieland, S., R. Thimme, R. H. Purcell, and F. V. Chisari. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 101: 6669-6674. https://doi.org/10.1073/pnas.0401771101
  65. Ando, K., L. G. Guidotti, S. Wirth, T. Ishikawa, G. Missale, T. Moriyama, R. D. Schreiber, H. J. Schlicht, S. N. Huang, and F. V. Chisari. 1994. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J. Immunol. 152: 3245-3253.
  66. Kondo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3: 409-413. https://doi.org/10.1038/nm0497-409
  67. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182: 1223-1230. https://doi.org/10.1084/jem.182.5.1223
  68. Kakimi, K., T. E. Lane, S. Wieland, V. C. Asensio, I. L. Campbell, F. V. Chisari, and L. G. Guidotti. 2001. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J. Exp. Med. 194: 1755-1766. https://doi.org/10.1084/jem.194.12.1755
  69. Sitia, G., M. Isogawa, K. Kakimi, S. F. Wieland, F. V. Chisari, and L. G. Guidotti. 2002. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 99: 13717-13722. https://doi.org/10.1073/pnas.172521999
  70. Sitia, G., M. Isogawa, M. Iannacone, I. L. Campbell, F. V. Chisari, and L. G. Guidotti. 2004. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 113: 1158-1167. https://doi.org/10.1172/JCI200421087
  71. Iannacone, M., G. Sitia, I. Narvaiza, Z. M. Ruggeri, and L. G. Guidotti. 2007. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin. Vaccine Immunol. 14: 1532-1535. https://doi.org/10.1128/CVI.00298-07
  72. Lang, P. A., C. Contaldo, P. Georgiev, A. M. El-Badry, M. Recher, M. Kurrer, L. Cervantes-Barragan, B. Ludewig, T. Calzascia, B. Bolinger, D. Merkler, B. Odermatt, M. Bader, R. Graf, P. A. Clavien, A. N. Hegazy, M. Lohning, N. L. Harris, P. S. Ohashi, H. Hengartner, R. M. Zinkernagel, and K. S. Lang. 2008. Aggravation of viral hepatitis by platelet-derived serotonin. Nat. Med. 14: 756-761. https://doi.org/10.1038/nm1780
  73. Tsui, L. V., L. G. Guidotti, T. Ishikawa, and F. V. Chisari. 1995. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 92: 12398-12402. https://doi.org/10.1073/pnas.92.26.12398
  74. Urbani, S., C. Boni, B. Amadei, P. Fisicaro, S. Cerioni, M. A. Valli, G. Missale, and C. Ferrari. 2005. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41: 826-831. https://doi.org/10.1002/hep.20614
  75. Barnaba, V., A. Franco, A. Alberti, C. Balsano, R. Benvenuto, and F. Balsano. 1989. Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J. Immunol. 143: 2650-2655.
  76. Burton, D. R., R. A. Williamson, and P. W. Parren. 2000. Antibody and virus: binding and neutralization. Virology 270: 1-3. https://doi.org/10.1006/viro.2000.0239
  77. Schilling, R., S. Ijaz, M. Davidoff, J. Y. Lee, S. Locarnini, R. Williams, and N. V. Naoumov. 2003. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J. Virol. 77: 8882-8892. https://doi.org/10.1128/JVI.77.16.8882-8892.2003
  78. Rehermann, B., C. Ferrari, C. Pasquinelli, and F. V. Chisari. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2: 1104-1108. https://doi.org/10.1038/nm1096-1104
  79. Moss, B., G. L. Smith, J. L. Gerin, and R. H. Purcell. 1984. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311: 67-69. https://doi.org/10.1038/311067a0
  80. Shouval, D., and D. Samuel. 2000. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32: 1189-1195. https://doi.org/10.1053/jhep.2000.19789
  81. Cooper, N. R. and G. R. Nemerow. 1983. Complement, viruses, and virus-infected cells. Springer Semin. Immunopathol. 6: 327-347. https://doi.org/10.1007/BF02116278

Cited by

  1. Multiplex qPCR for serodetection and serotyping of hepatitis viruses: A brief review vol.22, pp.20, 2015, https://doi.org/10.3748/wjg.v22.i20.4824
  2. Immune- and Nonimmune-Compartment-Specific Interferon Responses Are Critical Determinants of Herpes Simplex Virus-Induced Generalized Infections and Acute Liver Failure vol.90, pp.23, 2015, https://doi.org/10.1128/jvi.01473-16
  3. Apigenin inhibits D-galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARγ expressions in mice vol.493, pp.1, 2015, https://doi.org/10.1016/j.bbrc.2017.08.141
  4. Detection of Necroptosis in Ligand-Mediated and Hypoxia-Induced Injury of Hepatocytes Using a Novel Optic Probe-Detecting Receptor-Interacting Protein (RIP)1/RIP3 Binding vol.26, pp.3, 2015, https://doi.org/10.3727/096504017x15005102445191
  5. Therapeutic effects of mesenchymal stem cells combined with short hairpin RNA on liver injury induced by hepatitis B virus infection vol.17, pp.1, 2015, https://doi.org/10.3892/mmr.2017.8096
  6. Identification of serum β-catenin as a biomarker in patients with HBV-related liver diseases vol.16, pp.None, 2018, https://doi.org/10.1186/s12967-018-1645-x
  7. Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population vol.9, pp.None, 2015, https://doi.org/10.1038/s41598-019-42808-4
  8. Mechanism of KLF4 Protection against Acute Liver Injury via Inhibition of Apelin Signaling vol.2019, pp.None, 2015, https://doi.org/10.1155/2019/6140360
  9. Total flavonoids from Tetrastigma hemsleyanum ameliorates inflammatory stress in concanavalin A-induced autoimmune hepatitis mice by regulating Treg/Th17 immune homeostasis vol.27, pp.6, 2019, https://doi.org/10.1007/s10787-019-00599-0
  10. Protective effect of apigenin on d-galactosamine/LPS-induced hepatocellular injury by increment of Nrf-2 nucleus translocation vol.393, pp.6, 2015, https://doi.org/10.1007/s00210-019-01760-w
  11. Loss of hepatocyte cell division leads to liver inflammation and fibrosis vol.16, pp.11, 2015, https://doi.org/10.1371/journal.pgen.1009084
  12. Analysis of a stochastic HBV infection model with delayed immune response vol.18, pp.5, 2015, https://doi.org/10.3934/mbe.2021264
  13. Distinct Hepatitis B and HIV co‐infected populations in Canada vol.28, pp.3, 2015, https://doi.org/10.1111/jvh.13453
  14. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression vol.22, pp.11, 2015, https://doi.org/10.3390/ijms22115497
  15. Comparative expression of pro-inflammatory and apoptotic biosignatures in chronic HBV-infected patients with and without liver cirrhosis vol.161, pp.no.pa, 2015, https://doi.org/10.1016/j.micpath.2021.105231
  16. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus vol.11, pp.1, 2015, https://doi.org/10.1038/s41598-021-91196-1